Tweet
Conference on anti bodies, including anti-bodies for avian flu:
New Approaches to Discovery of Effective Prophylactic and Therapeutic Antibodies to Influenza, Including Avian Viruses
New ways to protect groups most vulnerable to influenza are needed, since Oseltamivir resistance is on the rise and influenza vaccines have been shown to be less effective in the elderly. There is preliminary and anecdotal evidence that immunoglobulins from survivors of the 1918 H1N1 pandemic and from individuals surviving H5N1 avian influenza may be therapeutically effective. We report the discovery of influenza virus neutralizing human monoclonal antibodies effective against a broad range of avian and human influenza strains.
Jaap Goudsmit, M.D., Ph.D., Chief Scientific Officer, Member of the Management Board, Crucell NV, The Netherlands
Neutralizing Antibody Solutions from H5N1 Avian Influenza Survivor Combinatorial Antibody Libraries
We have generated combinatorial antibody libraries from the bone marrow of convalescent H5N1 Avian influenza survivors that have yielded >300 unique antibodies against H5N1 viral antigens. Amongst these antibodies, we have identified several broadly neutralizing, anti-hemagglutinin antibodies for use as passive immunization against H5N1 viral infection. Remarkably three such antibodies neutralize a broad range of present and past H5 clades, as well as several relevant H1 subtype influenza viruses.
Ramesh R. Bhatt, Ph.D., Vice President, Research, Sea Lane Biotechnologies
A Unique Class of Protective Human Anti-M2 mAbs for Pandemic Influenza
M2, is a highly conserved, virally encoded transmembrane protein present on the surface of influenza A virus and infected cells. We have isolated mAbs directly from human B cells that recognize an unanticipated, conformational epitope within M2 using a novel antibody discovery platform. This unique class of human anti-M2 mAbs could be useful as therapeutic agents for protection from and treatment for pandemic influenza, and also as a tool for the design of a universal influenza vaccine.
Matthew Moyle, Ph.D., Senior Vice President, Research and Development, Chief Scientific Officer, Spaltudaq Corporation
Also new developments on cell culture (to produce vaccins or anti-bodies) are presented:
PER.C6® Cells: A Highly Efficient Production Platform for Antibodies
Yields of 8 g/L in fed-batch and 27 g/L using DSM's XD™ for IgGs and over 1.5 g/L in fed-batch for IgMs are now possible due to the ability to obtain stable clones producing 50 picograms of IgG per cell per day and 20 pcds of IgM, reliably, using the PER.C6® cell line. The workshop will focus on key aspects of the technology and economic impact relative to current approaches in manufacturing of protein therapeutics.
Marco A. Cacciuttolo, Ph.D., President & Chief Executive Officer, Percivia LLC
New Approaches to Discovery of Effective Prophylactic and Therapeutic Antibodies to Influenza, Including Avian Viruses
New ways to protect groups most vulnerable to influenza are needed, since Oseltamivir resistance is on the rise and influenza vaccines have been shown to be less effective in the elderly. There is preliminary and anecdotal evidence that immunoglobulins from survivors of the 1918 H1N1 pandemic and from individuals surviving H5N1 avian influenza may be therapeutically effective. We report the discovery of influenza virus neutralizing human monoclonal antibodies effective against a broad range of avian and human influenza strains.
Jaap Goudsmit, M.D., Ph.D., Chief Scientific Officer, Member of the Management Board, Crucell NV, The Netherlands
Neutralizing Antibody Solutions from H5N1 Avian Influenza Survivor Combinatorial Antibody Libraries
We have generated combinatorial antibody libraries from the bone marrow of convalescent H5N1 Avian influenza survivors that have yielded >300 unique antibodies against H5N1 viral antigens. Amongst these antibodies, we have identified several broadly neutralizing, anti-hemagglutinin antibodies for use as passive immunization against H5N1 viral infection. Remarkably three such antibodies neutralize a broad range of present and past H5 clades, as well as several relevant H1 subtype influenza viruses.
Ramesh R. Bhatt, Ph.D., Vice President, Research, Sea Lane Biotechnologies
A Unique Class of Protective Human Anti-M2 mAbs for Pandemic Influenza
M2, is a highly conserved, virally encoded transmembrane protein present on the surface of influenza A virus and infected cells. We have isolated mAbs directly from human B cells that recognize an unanticipated, conformational epitope within M2 using a novel antibody discovery platform. This unique class of human anti-M2 mAbs could be useful as therapeutic agents for protection from and treatment for pandemic influenza, and also as a tool for the design of a universal influenza vaccine.
Matthew Moyle, Ph.D., Senior Vice President, Research and Development, Chief Scientific Officer, Spaltudaq Corporation
Also new developments on cell culture (to produce vaccins or anti-bodies) are presented:
PER.C6® Cells: A Highly Efficient Production Platform for Antibodies
Yields of 8 g/L in fed-batch and 27 g/L using DSM's XD™ for IgGs and over 1.5 g/L in fed-batch for IgMs are now possible due to the ability to obtain stable clones producing 50 picograms of IgG per cell per day and 20 pcds of IgM, reliably, using the PER.C6® cell line. The workshop will focus on key aspects of the technology and economic impact relative to current approaches in manufacturing of protein therapeutics.
Marco A. Cacciuttolo, Ph.D., President & Chief Executive Officer, Percivia LLC
Comment